Literature DB >> 35663104

Chronic Myelomonocytic Leukemia: Hematopathology Perspective.

Siba El Hussein1, Sa A Wang1, Naveen Pemmaraju2, Joseph D Khoury1, Sanam Loghavi1.   

Abstract

Our understanding of chronic myelomonocytic leukemia (CMML) has evolved tremendously over the past decade. Large-scale sequencing studies have led to increased insight into the genomic landscape of CMML and clinical implications of these changes. This in turn has resulted in refined and improved risk stratification models, which to date remain versatile and subject to remodeling, as new and evolving studies continue to refine our understanding of this disease. In this article, we present an up-to-date review of CMML from a hematopathology perspective, while providing a clinically practical summary that sheds light on the constant evolution of our understanding of this disease. © Innovative Healthcare Institute 2021.

Entities:  

Keywords:  ASXL1; CMML; MDS; MPN; NRAS; SRSF2; chronic myelomonocytic leukemia; monocyte; myelodysplastic; myelproliferative

Year:  2021        PMID: 35663104      PMCID: PMC9138437          DOI: 10.36401/JIPO-21-1

Source DB:  PubMed          Journal:  J Immunother Precis Oncol        ISSN: 2590-017X


  56 in total

1.  More on Blastic Plasmacytoid Dendritic-Cell Neoplasms.

Authors:  Naveen Pemmaraju; Marina Konopleva; Andrew A Lane
Journal:  N Engl J Med       Date:  2019-02-14       Impact factor: 91.245

2.  Revised international prognostic scoring system for myelodysplastic syndromes.

Authors:  Peter L Greenberg; Heinz Tuechler; Julie Schanz; Guillermo Sanz; Guillermo Garcia-Manero; Francesc Solé; John M Bennett; David Bowen; Pierre Fenaux; Francois Dreyfus; Hagop Kantarjian; Andrea Kuendgen; Alessandro Levis; Luca Malcovati; Mario Cazzola; Jaroslav Cermak; Christa Fonatsch; Michelle M Le Beau; Marilyn L Slovak; Otto Krieger; Michael Luebbert; Jaroslaw Maciejewski; Silvia M M Magalhaes; Yasushi Miyazaki; Michael Pfeilstöcker; Mikkael Sekeres; Wolfgang R Sperr; Reinhard Stauder; Sudhir Tauro; Peter Valent; Teresa Vallespi; Arjan A van de Loosdrecht; Ulrich Germing; Detlef Haase
Journal:  Blood       Date:  2012-06-27       Impact factor: 22.113

3.  Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia.

Authors:  Dorothée Selimoglu-Buet; Orianne Wagner-Ballon; Véronique Saada; Valérie Bardet; Raphaël Itzykson; Laura Bencheikh; Margot Morabito; Elisabeth Met; Camille Debord; Emmanuel Benayoun; Anne-Marie Nloga; Pierre Fenaux; Thorsten Braun; Christophe Willekens; Bruno Quesnel; Lionel Adès; Michaela Fontenay; Philippe Rameau; Nathalie Droin; Serge Koscielny; Eric Solary
Journal:  Blood       Date:  2015-04-07       Impact factor: 22.113

4.  Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations.

Authors:  Hatice D Gur; Sanam Loghavi; Guillermo Garcia-Manero; Mark Routbort; Rashmi Kanagal-Shamanna; Andres Quesada; Haitham Khogeer; Sherry Pierce; L Jeffrey Medeiros; Hagop Kantarjian; Joseph D Khoury
Journal:  Am J Surg Pathol       Date:  2018-06       Impact factor: 6.394

5.  Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.

Authors:  Anna M Jankowska; Hideki Makishima; Ramon V Tiu; Hadrian Szpurka; Yun Huang; Fabiola Traina; Valeria Visconte; Yuka Sugimoto; Courtney Prince; Christine O'Keefe; Eric D Hsi; Alan List; Mikkael A Sekeres; Anjana Rao; Michael A McDevitt; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

6.  Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management.

Authors:  Mrinal M Patnaik; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2020-01       Impact factor: 10.047

7.  Cytogenetic risk stratification in chronic myelomonocytic leukemia.

Authors:  Esperanza Such; José Cervera; Dolors Costa; Francesc Solé; Teresa Vallespí; Elisa Luño; Rosa Collado; María J Calasanz; Jesús M Hernández-Rivas; Juan C Cigudosa; Benet Nomdedeu; Mar Mallo; Felix Carbonell; Javier Bueno; María T Ardanaz; Fernando Ramos; Mar Tormo; Reyes Sancho-Tello; Consuelo del Cañizo; Valle Gómez; Victor Marco; Blanca Xicoy; Santiago Bonanad; Carmen Pedro; Teresa Bernal; Guillermo F Sanz
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

8.  Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1976-08       Impact factor: 6.998

9.  Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia.

Authors:  Sanam Loghavi; Jonathan L Curry; Guillermo Garcia-Manero; Keyur P Patel; Jie Xu; Joseph D Khoury; Carlos A Torres-Cabala; Priyadharsini Nagarajan; Phyu P Aung; Bernard R Gibson; Brandon P Goodwin; Brent C Kelly; Brinda R Korivi; L Jeffrey Medeiros; Victor G Prieto; Hagop M Kantarjian; Carlos E Bueso-Ramos; Michael T Tetzlaff
Journal:  J Cutan Pathol       Date:  2017-09-27       Impact factor: 1.587

10.  Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients.

Authors:  Giacomo Coltro; Abhishek A Mangaonkar; Terra L Lasho; Christy M Finke; Prateek Pophali; Ryan Carr; Naseema Gangat; Moritz Binder; Animesh Pardanani; Martin Fernandez-Zapico; Keith D Robertson; Alberto Bosi; Nathalie Droin; Alessandro M Vannucchi; Ayalew Tefferi; Anthony Hunter; Eric Padron; Eric Solary; Mrinal M Patnaik
Journal:  Leukemia       Date:  2019-12-13       Impact factor: 11.528

View more
  1 in total

1.  Rare Blood Cancers in 2021: Importance of Continued Exchange of Ideas.

Authors:  Naveen Pemmaraju
Journal:  J Immunother Precis Oncol       Date:  2021-08-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.